enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder Growth Opportunities F. Forbion purchased 10,153 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were bought at an average price of $6.37 per share, for a total transaction of $64,674.61. Following the acquisition, the insider now owns 2,446,223 shares in the company, valued at $15,582,440.51. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
enGene Stock Down 3.0 %
ENGN stock opened at $9.02 on Friday. The stock has a market cap of $398.38 million, a P/E ratio of -5.24 and a beta of -0.69. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. enGene Holdings Inc. has a twelve month low of $4.42 and a twelve month high of $43.00. The company’s 50 day moving average is $6.71 and its two-hundred day moving average is $9.73.
enGene (NASDAQ:ENGN – Get Free Report) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. Research analysts expect that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Research Report on enGene
Institutional Trading of enGene
Institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new position in shares of enGene during the first quarter worth approximately $17,095,000. SR One Capital Management LP purchased a new position in enGene in the 2nd quarter valued at $4,715,000. Logos Global Management LP raised its position in enGene by 50.0% during the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. acquired a new stake in shares of enGene in the 1st quarter worth $2,039,000. 64.16% of the stock is owned by hedge funds and other institutional investors.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Stories
- Five stocks we like better than enGene
- What Are Dividend Contenders? Investing in Dividend Contenders
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Read Stock Charts for Beginners
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.